(i) a CO_2 donor, and

(ii) an acidic component;

(B) a pharmaceutically active substance, and

(C) an ancillary substance comprising at least one ingredient selected from the group consisting of fusible sugars, sugar alcohols, and sugar substitutes,

wherein at least one of said CO_2 donor and said acidic component is dispersed in said ingredient.

9 (New). The stabilized medicament of claim 8, wherein said ingredient has a melting point from 30° C to 200° C.

10 (New). The stabilized medicament of claim 9, wherein said ingredient has a melting point from 40° C to 160° C.

11 (New). A process for producing a stabilized medicament, said stabilized medicament comprising:

(A) an effervescent system comprising:

(i) a CO_2 donor, and

(ii) an acidic component;

(B) a pharmaceutically active substance, and

(C) an ancillary substance comprising at least one ingredient selected from the group consisting of fusible sugars, sugar alcohols, and sugar substitutes,

wherein said process comprises the steps of: (a) at least partially melting said ancillary substance, (b) mixing at least one of said CO_2 donor and said acidic component with said partially melted ancillary substance to form a blend, (c) cooling said blend, and (d) combining said blend, said pharmaceutically active substance and any remaining portion of said effervescent system to form said medicament.

12 (New). The process of claim 11, wherein said step of at least partially melting said ancillary substance is carried out at a temperature from 30° C to 200° C.

13 (New). The process of claim 12, wherein said step of at least partially melting said ancillary substance is carried out at a temperature from 40° C to 160° C.

14. (New). The process of claim 11, wherein said blend is comminuted after cooling.

15 (New). The process of claim 11, wherein said medicament is tabletted.

REMARKS

Bayer, the assignee of the present application, submits these new claims to cover embodiments of the invention that may be sold in the marketplace. No diminution of the scope of the claims as a result of any action of the Examiner is contemplated. Indeed, as will be set forth below, Bayer contends that the reference cited by the Examiner should not be cited against this invention at all.